Ligand Pharmaceuticals is experiencing a sharp decline following news of a target price downgrade.
As of 10:22 a.m. on November 16, shares of Ligand Pharmaceuticals were trading at 55,100 won, down 11.41% from the previous trading day, according to the Korea Exchange.
The drop is attributed to technology transfer results falling short of investor expectations, leading to a reduction in the target price.
Ligand Pharmaceuticals reported a 65% decrease in revenue for the third quarter compared to the same period last year, totaling 14.5 billion won, with an operating loss of 45.1 billion won. This decline was influenced by the recognition of advance payments from existing technology transfer contracts with Johnson & Johnson and Ono Pharmaceutical, which raised the comparative benchmark.
Hana Securities has lowered its target price for Ligand Pharmaceuticals from 220,000 won to 140,000 won, a reduction of approximately 36%. While the technology transfer performance did not meet expectations, the firm noted that the clinical development of new drug candidates is progressing smoothly and maintained a 'buy' rating.
Founded in 2006 and listed on the KOSDAQ in 2013, Ligand Pharmaceuticals is advancing technology transfers and joint development with global pharmaceutical companies based on its proprietary ADC (antibody-drug conjugate) technology, 'ConjuALL.'
Once highlighted as the first direct investment case by the National Growth Fund in a biotech company, Ligand Pharmaceuticals has seen its shares decline nearly 79% since peaking at 260,000 won on April 26.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.